Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain
Alzheimer's & Dementia · 2026-06 · 22 (6)
DOI: 10.1002/alz.71509 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 01.06.2026. Verfasst von Martine B Grenon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Building for Transformative Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Brain, Antibodies, Monoclonal, Amyloid beta-Peptides. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Acumen Pharmaceuticals (US), National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
INTRODUCTION Immunotherapy targeting amyloid beta (Aβ) is limited by amyloid‐related imaging abnormalities (ARIA), hypothesized to result from the direct binding of anti‐Aβ monoclonal antibodies (mAbs) to vascular cerebral amyloid angiopathy (CAA), eliciting an immune response. METHODS Immunofluorescent staining was used to characterize ex vivo plaque and vascular binding of recombinant FDA‐approved lecanemab and clinical candidate sabirnetug (ACU193) in 30 min and 24 h fixed APP:hE4 mouse brain tissue. RESULTS Fixation time was a key factor influencing Aβ antigen labeling with prolonged fixation differentially affecting pan‐Aβ and mAb immunoreactivity. Compared with ACU193, lecanemab showed greater cortical plaque and cerebellar vascular labeling and encompassed a larger fraction of total pan‐Aβ and β‐pleated‐sheet‐rich signal, reflecting both mAb target abundance and selectivity. DISCUSSION These findings emphasize that experimental protocols and antibody properties jointly shape the observed mAb binding patterns and highlight differences that may contribute to antibody‐specific ARIA risk observed clinically.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Building for Transformative Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
- Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.
- Acumen Pharmaceuticals, Newton, Massachusetts, USA.
Förderung
- NINDS NIH HHS
- Acumen Pharmaceuticals (US)
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Grenon, M. B., Cline, E. N., Jerecic, J., Johnson, E., Siemers, E., & Lemere, C. A. (2026). Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain. Alzheimer's & Dementia, 22(6). https://doi.org/10.1002/alz.71509
Vancouver
Grenon MB, Cline EN, Jerecic J, Johnson E, Siemers E, Lemere CA. Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain. Alzheimer's & Dementia. 2026;22(6). doi:10.1002/alz.71509
BibTeX
@article{Grenon2026,
author = {Grenon, Martine B and Cline, Erika N and Jerecic, Jasna and Johnson, Elizabeth and Siemers, Eric and Lemere, Cynthia A},
title = {Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {6},
doi = {10.1002/alz.71509}
}
EUVIMED